Plain-English translation of NCT02971085 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study is building a registry of Korean men with low-risk prostate cancer who choose active surveillance — a watchful waiting approach where doctors monitor the cancer closely with regular tests instead of treating it right away. Researchers want to understand how well this strategy works specifically for Korean patients, since cancer behavior and patient characteristics can differ from Western populations.
Many men with low-risk prostate cancer are being treated unnecessarily, which can cause side effects without improving survival. This study exists to gather solid evidence about whether active surveillance is a safe and effective first-line approach for Korean men with early-stage, slow-growing prostate cancer.
You likely qualify if…
You likely don't qualify if…
You would join a registry and commit to regular monitoring appointments instead of having surgery or radiation. These visits would include PSA blood tests, imaging scans, and possibly repeat biopsies to make sure your cancer remains low-risk. The study will track your health outcomes over time to help doctors and future patients understand whether active surveillance is a safe choice for men like you.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
South Korea
Sponsor
Seoul National University Hospital
Enrollment target
~410 participants
Started
December 2016
Primary completion
January 2022
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
40 Years – 80 Years
Sex
Male only
Last updated on clinicaltrials.gov in February 2019.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Min Ji Seo, Bachelor
Seoul National University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.